Fresenius Medical Care AG & Co. KGaA Logo

Fresenius Medical Care AG & Co. KGaA

FMS

(2.2)
Stock Price

22,81 USD

2.99% ROA

4.68% ROE

10.08x PER

Market Cap.

10.692.673.911,20 USD

59.39% DER

3.78% Yield

3.42% NPM

Fresenius Medical Care AG & Co. KGaA Stock Analysis

Fresenius Medical Care AG & Co. KGaA Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Fresenius Medical Care AG & Co. KGaA Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.76x) suggests it's undervalued, making it an attractive opportunity for investors.

2 Dividend

Investors can trust the company's impressive dividend track record, consistently distributing dividends over the past five years, showcasing a strong commitment to rewarding shareholders.

3 ROE

ROE in an average range (3.89%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 ROA

The stock's ROA (2.94%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 DER

The stock maintains a fair debt to equity ratio (93%), indicating a reasonable balance between the money it owes and the ownership it possesses.

6 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

7 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (480), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

8 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

10 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

11 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Fresenius Medical Care AG & Co. KGaA Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Fresenius Medical Care AG & Co. KGaA Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Fresenius Medical Care AG & Co. KGaA Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Fresenius Medical Care AG & Co. KGaA Revenue
Year Revenue Growth
1997 2.961.269.766
1998 2.989.170.162 0.93%
1999 3.816.579.935 21.68%
2000 4.473.332.622 14.68%
2001 5.461.436.093 18.09%
2002 4.844.991.918 -12.72%
2003 4.389.007.971 -10.39%
2004 4.594.272.515 4.47%
2005 5.717.514.499 19.65%
2006 6.439.636.102 11.21%
2007 6.666.871.763 3.41%
2008 7.623.256.103 12.55%
2009 7.850.289.046 2.89%
2010 9.063.019.131 13.38%
2011 9.872.028.543 8.19%
2012 10.434.945.231 5.39%
2013 10.580.072.098 1.37%
2014 13.019.603.520 18.74%
2015 15.309.579.080 14.96%
2016 17.030.495.240 10.1%
2017 17.784.000.000 4.24%
2018 16.547.000.000 -7.48%
2019 17.477.000.000 5.32%
2020 17.859.000.000 2.14%
2021 17.619.000.000 -1.36%
2022 19.398.000.000 9.17%
2023 19.744.948.000 1.76%
2023 19.454.000.000 -1.5%
2024 19.065.752.000 -2.04%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Fresenius Medical Care AG & Co. KGaA Research and Development Expenses
Year Research and Development Expenses Growth
1997 0
1998 26.602.992 100%
1999 32.286.249 17.6%
2000 34.002.471 5.05%
2001 40.123.587 15.26%
2002 45.202.226 11.24%
2003 39.452.968 -14.57%
2004 37.890.195 -4.12%
2005 43.021.816 11.93%
2006 38.864.193 -10.7%
2007 45.626.130 14.82%
2008 57.638.883 20.84%
2009 65.475.627 11.97%
2010 72.582.410 9.79%
2011 85.513.972 15.12%
2012 84.408.664 -1.31%
2013 91.105.464 7.35%
2014 100.327.920 9.19%
2015 128.052.400 21.65%
2016 154.036.080 16.87%
2017 131.000.000 -17.58%
2018 134.000.000 2.24%
2019 168.000.000 20.24%
2020 194.000.000 13.4%
2021 221.000.000 12.22%
2022 229.000.000 3.49%
2023 212.164.000 -7.94%
2023 232.000.000 8.55%
2024 182.340.000 -27.23%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Fresenius Medical Care AG & Co. KGaA General and Administrative Expenses
Year General and Administrative Expenses Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Fresenius Medical Care AG & Co. KGaA EBITDA
Year EBITDA Growth
1997 2.961.269.766
1998 750.681.864 -294.48%
1999 1.436.445.929 47.74%
2000 1.004.703.570 -42.97%
2001 1.079.941.516 6.97%
2002 862.935.300 -25.15%
2003 773.235.942 -11.6%
2004 800.331.162 3.39%
2005 1.005.041.294 20.37%
2006 1.202.144.892 16.4%
2007 1.332.955.423 9.81%
2008 1.517.790.642 12.18%
2009 1.559.237.754 2.66%
2010 1.843.988.132 15.44%
2011 2.076.794.251 11.21%
2012 2.139.663.724 2.94%
2013 2.124.698.496 -0.7%
2014 2.497.507.320 14.93%
2015 2.891.240.260 13.62%
2016 3.289.906.400 12.12%
2017 3.141.000.000 -4.74%
2018 3.101.000.000 -1.29%
2019 2.303.000.000 -34.65%
2020 2.315.000.000 0.52%
2021 1.925.000.000 -20.26%
2022 1.580.000.000 -21.84%
2023 3.213.600.000 50.83%
2023 3.438.617.000 6.54%
2024 2.945.828.000 -16.73%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Fresenius Medical Care AG & Co. KGaA Gross Profit
Year Gross Profit Growth
1997 2.961.269.766
1998 1.346.435.406 -119.93%
1999 1.689.476.788 20.3%
2000 1.561.702.072 -8.18%
2001 1.842.223.359 15.23%
2002 1.578.137.380 -16.73%
2003 1.452.203.849 -8.67%
2004 1.538.715.647 5.62%
2005 1.969.492.386 21.87%
2006 2.180.295.406 9.67%
2007 2.301.639.117 5.27%
2008 2.606.746.672 11.7%
2009 2.674.242.115 2.52%
2010 3.116.415.720 14.19%
2011 3.487.946.857 10.65%
2012 3.479.191.443 -0.25%
2013 3.431.452.339 -1.39%
2014 4.108.510.560 16.48%
2015 4.876.052.460 15.74%
2016 5.495.855.200 11.28%
2017 6.004.000.000 8.46%
2018 5.155.000.000 -16.47%
2019 5.396.000.000 4.47%
2020 5.537.000.000 2.55%
2021 5.077.000.000 -9.06%
2022 5.310.000.000 4.39%
2023 4.915.988.000 -8.01%
2023 4.925.000.000 0.18%
2024 4.665.956.000 -5.55%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Fresenius Medical Care AG & Co. KGaA Net Profit
Year Net Profit Growth
1997 81.999.918
1998 16.285.806 -403.51%
1999 -247.000.542 106.59%
2000 225.804.735 209.39%
2001 71.204.194 -217.12%
2002 276.161.176 74.22%
2003 262.966.855 -5.02%
2004 296.545.884 11.32%
2005 384.120.523 22.8%
2006 406.687.076 5.55%
2007 491.857.953 17.32%
2008 587.319.812 16.25%
2009 621.978.678 5.57%
2010 735.746.932 15.46%
2011 826.448.868 10.97%
2012 897.393.757 7.91%
2013 803.760.140 -11.65%
2014 859.366.200 6.47%
2015 941.185.140 8.69%
2016 1.181.894.120 20.37%
2017 1.280.000.000 7.66%
2018 1.982.000.000 35.42%
2019 1.200.000.000 -65.17%
2020 1.164.377.000 -3.06%
2021 969.308.000 -20.12%
2022 673.405.000 -43.94%
2023 337.404.000 -99.58%
2023 498.997.000 32.38%
2024 748.000.000 33.29%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Fresenius Medical Care AG & Co. KGaA Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1997 0
1998 0 0%
1999 -1 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 1 0%
2005 1 0%
2006 1 0%
2007 1 0%
2008 1 0%
2009 1 100%
2010 1 0%
2011 1 0%
2012 1 0%
2013 1 0%
2014 1 0%
2015 2 0%
2016 2 0%
2017 2 50%
2018 3 33.33%
2019 4 0%
2020 4 0%
2021 3 0%
2022 2 -50%
2023 1 0%
2023 2 100%
2024 3 50%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Fresenius Medical Care AG & Co. KGaA Free Cashflow
Year Free Cashflow Growth
1998 -96.862.176
1999 189.514.758 151.11%
2000 173.796.444 -9.04%
2001 167.488.439 -3.77%
2002 296.143.050 43.44%
2003 367.444.528 19.4%
2004 405.068.202 9.29%
2005 300.181.755 -34.94%
2006 333.866.247 10.09%
2007 425.193.446 21.48%
2008 236.364.029 -79.89%
2009 533.939.400 55.73%
2010 634.976.541 15.91%
2011 -722.942.350 187.83%
2012 1.031.188.192 170.11%
2013 931.923.343 -10.65%
2014 7.401.240 -12491.45%
2015 65.855.520 88.76%
2016 93.182.320 29.33%
2017 407.000.000 77.11%
2018 2.000.000 -20250%
2019 329.000.000 99.39%
2020 2.145.000.000 84.66%
2021 806.000.000 -166.13%
2022 756.000.000 -6.61%
2023 622.976.000 -21.35%
2023 1.944.205.000 67.96%
2024 277.236.000 -601.28%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Fresenius Medical Care AG & Co. KGaA Operating Cashflow
Year Operating Cashflow Growth
1998 228.512.880
1999 348.795.445 34.49%
2000 416.596.560 16.28%
2001 476.816.569 12.63%
2002 524.055.356 9.01%
2003 598.713.706 12.47%
2004 610.683.224 1.96%
2005 565.944.370 -7.91%
2006 687.853.712 17.72%
2007 822.751.819 16.4%
2008 730.119.339 -12.69%
2009 934.568.440 21.88%
2010 1.028.693.187 9.15%
2011 1.115.661.300 7.8%
2012 1.541.817.096 27.64%
2013 1.473.565.084 -4.63%
2014 1.530.411.960 3.71%
2015 1.792.733.600 14.63%
2016 2.034.797.600 11.9%
2017 2.192.000.000 7.17%
2018 2.062.000.000 -6.3%
2019 2.567.000.000 19.67%
2020 4.233.000.000 39.36%
2021 2.489.000.000 -70.07%
2022 2.167.000.000 -14.86%
2023 759.756.000 -185.22%
2023 2.628.801.000 71.1%
2024 442.423.000 -494.18%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Fresenius Medical Care AG & Co. KGaA Capital Expenditure
Year Capital Expenditure Growth
1998 325.375.056
1999 159.280.686 -104.28%
2000 242.800.115 34.4%
2001 309.328.130 21.51%
2002 227.912.305 -35.72%
2003 231.269.178 1.45%
2004 205.615.022 -12.48%
2005 265.762.614 22.63%
2006 353.987.464 24.92%
2007 397.558.373 10.96%
2008 493.755.309 19.48%
2009 400.629.040 -23.25%
2010 393.716.645 -1.76%
2011 1.838.603.650 78.59%
2012 510.628.903 -260.07%
2013 541.641.741 5.73%
2014 1.523.010.720 64.44%
2015 1.726.878.080 11.81%
2016 1.941.615.280 11.06%
2017 1.785.000.000 -8.77%
2018 2.060.000.000 13.35%
2019 2.238.000.000 7.95%
2020 2.088.000.000 -7.18%
2021 1.683.000.000 -24.06%
2022 1.411.000.000 -19.28%
2023 136.780.000 -931.58%
2023 684.596.000 80.02%
2024 165.187.000 -314.44%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Fresenius Medical Care AG & Co. KGaA Equity
Year Equity Growth
1998 2.026.687.554
1999 2.011.521.394 -0.75%
2000 2.874.820.359 30.03%
2001 2.963.724.820 3%
2002 2.696.620.161 -9.91%
2003 2.586.779.023 -4.25%
2004 2.694.634.387 4%
2005 3.367.201.997 19.97%
2006 3.747.019.510 10.14%
2007 3.896.448.731 3.84%
2008 4.282.945.651 9.02%
2009 5.052.365.627 15.23%
2010 5.657.228.680 10.69%
2011 6.219.464.550 9.04%
2012 6.961.977.575 10.67%
2013 6.868.861.783 -1.36%
2014 8.727.754.376 21.3%
2015 10.157.169.418 14.07%
2016 11.510.239.583 11.76%
2017 11.836.084.000 2.75%
2018 14.045.547.000 15.73%
2019 14.496.324.000 3.11%
2020 13.447.230.000 -7.8%
2021 15.259.254.000 11.87%
2022 16.908.726.000 9.76%
2023 15.434.568.000 -9.55%
2023 14.826.535.000 -4.1%
2024 15.187.355.000 2.38%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Fresenius Medical Care AG & Co. KGaA Assets
Year Assets Growth
1998 4.842.597.204
1999 5.716.660.701 15.29%
2000 6.366.030.417 10.2%
2001 7.323.408.799 13.07%
2002 6.461.087.998 -13.35%
2003 5.957.861.179 -8.45%
2004 5.873.069.564 -1.44%
2005 6.740.211.161 12.87%
2006 9.883.824.346 31.81%
2007 9.718.959.655 -1.7%
2008 10.717.400.057 9.32%
2009 11.042.425.160 2.94%
2010 12.853.475.605 14.09%
2011 15.070.686.150 14.71%
2012 16.881.580.127 10.73%
2013 16.742.973.527 -0.83%
2014 20.926.594.920 19.99%
2015 23.354.013.780 10.39%
2016 25.609.924.560 8.81%
2017 24.025.000.000 -6.6%
2018 26.242.000.000 8.45%
2019 32.935.000.000 20.32%
2020 31.689.000.000 -3.93%
2021 34.367.000.000 7.79%
2022 35.754.000.000 3.88%
2023 35.634.696.000 -0.33%
2023 33.929.808.000 -5.02%
2024 33.896.203.999 -0.1%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Fresenius Medical Care AG & Co. KGaA Liabilities
Year Liabilities Growth
1998 2.815.909.650
1999 3.705.139.306 24%
2000 3.491.210.057 -6.13%
2001 4.359.683.979 19.92%
2002 3.764.467.836 -15.81%
2003 3.371.082.156 -11.67%
2004 3.178.435.176 -6.06%
2005 3.373.009.162 5.77%
2006 6.136.804.836 45.04%
2007 5.822.510.923 -5.4%
2008 6.434.454.405 9.51%
2009 6.135.766.360 -4.87%
2010 7.196.246.925 14.74%
2011 8.851.221.600 18.7%
2012 9.919.602.551 10.77%
2013 9.874.111.743 -0.46%
2014 12.679.968.840 22.13%
2015 13.753.742.420 7.81%
2016 14.716.150.680 6.54%
2017 13.197.000.000 -11.51%
2018 13.340.000.000 1.07%
2019 19.708.000.000 32.31%
2020 19.358.000.000 -1.81%
2021 20.388.000.000 5.05%
2022 20.305.000.000 -0.41%
2023 20.200.128.000 -0.52%
2023 19.103.273.000 -5.74%
2024 18.708.849.000 -2.11%

Fresenius Medical Care AG & Co. KGaA Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
66.17
Net Income per Share
1.81
Price to Earning Ratio
10.08x
Price To Sales Ratio
0.55x
POCF Ratio
2.61
PFCF Ratio
7.85
Price to Book Ratio
0.38
EV to Sales
1.1
EV Over EBITDA
6.78
EV to Operating CashFlow
10.42
EV to FreeCashFlow
15.67
Earnings Yield
0.1
FreeCashFlow Yield
0.13
Market Cap
10,69 Bil.
Enterprise Value
21,35 Bil.
Graham Number
43.94
Graham NetNet
-45.87

Income Statement Metrics

Net Income per Share
1.81
Income Quality
3.2
ROE
0.04
Return On Assets
0.02
Return On Capital Employed
0.06
Net Income per EBT
0.56
EBT Per Ebit
0.76
Ebit per Revenue
0.08
Effective Tax Rate
0.29

Margins

Sales, General, & Administrative to Revenue
0.03
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.25
Operating Profit Margin
0.08
Pretax Profit Margin
0.06
Net Profit Margin
0.03

Dividends

Dividend Yield
0.04
Dividend Yield %
3.78
Payout Ratio
0.66
Dividend Per Share
0.69

Operating Metrics

Operating Cashflow per Share
6.98
Free CashFlow per Share
4.64
Capex to Operating CashFlow
0.33
Capex to Revenue
0.04
Capex to Depreciation
0.39
Return on Invested Capital
0.04
Return on Tangible Assets
0.03
Days Sales Outstanding
76.37
Days Payables Outstanding
19.73
Days of Inventory on Hand
56.08
Receivables Turnover
4.78
Payables Turnover
18.5
Inventory Turnover
6.51
Capex per Share
2.34

Balance Sheet

Cash per Share
3,72
Book Value per Share
51,76
Tangible Book Value per Share
-3.32
Shareholders Equity per Share
47.48
Interest Debt per Share
29.58
Debt to Equity
0.59
Debt to Assets
0.24
Net Debt to EBITDA
3.39
Current Ratio
1.46
Tangible Asset Value
-0,97 Bil.
Net Current Asset Value
-10,02 Bil.
Invested Capital
26177845000
Working Capital
2,75 Bil.
Intangibles to Total Assets
0.48
Average Receivables
4,03 Bil.
Average Payables
0,75 Bil.
Average Inventory
2221724000
Debt to Market Cap
0.77

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Fresenius Medical Care AG & Co. KGaA Dividends
Year Dividends Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 1 0%
2005 1 0%
2006 1 0%
2007 1 0%
2008 1 100%
2009 1 0%
2010 1 0%
2011 1 0%
2012 1 0%
2013 0 0%
2014 1 0%
2015 0 0%
2016 0 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 1 0%
2021 1 0%
2022 1 0%
2023 1 0%
2024 1 0%

Fresenius Medical Care AG & Co. KGaA Profile

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

CEO
Ms. Helen Giza
Employee
113.079
Address
Else-KrOener Strasse 1
Bad Homburg, 61352

Fresenius Medical Care AG & Co. KGaA Executives & BODs

Fresenius Medical Care AG & Co. KGaA Executives & BODs
# Name Age
1 Dr. Gail-Suzanne Brown
Senior Vice President of Research & Development
70
2 Dr. Katarzyna Mazur-Hofsab Ph.D.
Chief Executive Officer of Care Enablement & Member of Management Board
70
3 Ms. Helen Giza
Chair of Management Board & Chief Executive Officer
70
4 Mr. Joachim Weith
Senior Vice President of Corporate Communications & Governmental Affairs
70
5 Mr. Jorg Haring
Global Head of Legal, Compliance & Human Resources and Labor Director
70
6 Mr. Martin Fischer
Chief Financial Officer & Member of the Management Board
70
7 Dr. Franklin W. Maddux F.A.C.P.
Global Chief Medical Officer & Member of Management Board
70
8 Mr. Craig Cordola FACHE, M.B.A., M.H.A.
Chief Executive Officer of Care Delivery & Member of Management Board
70
9 Dr. Dominik Heger
Executive Vice President and Head of Investor Relations, Strategic Development & Communications
70
10 Mr. Glenn Slater
Senior Vice President of Manufacturing and Supply Chain Operations
70

Fresenius Medical Care AG & Co. KGaA Competitors